Login to Your Account



Catalyst Biosciences Partners with MedImmune in $195M Deal

By Catherine Hollingsworth


Wednesday, July 8, 2009
Catalyst Biosciences has secured another big deal focused on its Alterase drug discovery engine, this time partnering with MedImmune, the global biologics unit of AstraZeneca plc, to develop drug candidates against two targets, one of which will address inflammatory and autoimmune diseases. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription